Header Logo

Connection

RAYNE ROUCE to Male

Back to Details
This is a "connection" page, showing publications RAYNE ROUCE has written about Male.
RAYNE ROUCE
Connection Strength
0.230
Male
  1. EBV and post-transplant lymphoproliferative disorder: a complex relationship. Hematology Am Soc Hematol Educ Program. 2024 12 06; 2024(1):728-735.
    View in: PubMed
    Score: 0.037
  2. Chimeric antigen receptor T cells for mature B-cell lymphoma and Burkitt lymphoma. Hematology Am Soc Hematol Educ Program. 2020 12 04; 2020(1):487-493.
    View in: PubMed
    Score: 0.028
  3. Gene Therapy: Current Applications and Future Possibilities. Adv Pediatr. 2019 08; 66:37-54.
    View in: PubMed
    Score: 0.025
  4. The TGF-?/SMAD pathway is an important mechanism for NK cell immune evasion in childhood B-acute lymphoblastic leukemia. Leukemia. 2016 Apr; 30(4):800-11.
    View in: PubMed
    Score: 0.020
  5. More than Memory: Potential of Adaptive Natural Killer Cells. Biol Blood Marrow Transplant. 2015 Sep; 21(9):1534-6.
    View in: PubMed
    Score: 0.019
  6. Real-world data for tisagenlecleucel in patients with R/R B-ALL: subgroup analyses from the CIBMTR registry. Blood Adv. 2025 Oct 28; 9(20):5249-5262.
    View in: PubMed
    Score: 0.010
  7. Characterization and prediction of prolonged severe neutropenia in pediatric patients receiving tisagenlecleucel. Blood Adv. 2025 Oct 14; 9(19):5070-5084.
    View in: PubMed
    Score: 0.010
  8. Social determinants of health and access to allogeneic hematopoietic cell transplantation for acute myeloid leukemia. Blood. 2025 Jun 19; 145(25):3041-3051.
    View in: PubMed
    Score: 0.009
  9. Differential antibody response to EBV proteome following EBVST immunotherapy in EBV-associated lymphomas. Blood Adv. 2025 Apr 08; 9(7):1658-1669.
    View in: PubMed
    Score: 0.009
  10. Cardiovascular Complications of Immune Effector Cell Therapies in Pediatric Hematological and Solid Tumors. Pediatr Blood Cancer. 2025 Apr; 72(4):e31557.
    View in: PubMed
    Score: 0.009
  11. Risk of T-cell malignancy after CAR T-cell therapy in children, adolescents, and young adults. Blood Adv. 2024 07 09; 8(13):3544-3548.
    View in: PubMed
    Score: 0.009
  12. Prolonged cytopenias after immune effector cell therapy and lymphodepletion in patients with leukemia, lymphoma and solid tumors. Cytotherapy. 2024 Sep; 26(9):1026-1032.
    View in: PubMed
    Score: 0.009
  13. Genetic errors of immunity distinguish pediatric nonmalignant lymphoproliferative disorders. J Allergy Clin Immunol. 2022 02; 149(2):758-766.
    View in: PubMed
    Score: 0.007
  14. T-Cell Therapy for Lymphoma Using Nonengineered Multiantigen-Targeted T Cells Is Safe and Produces Durable Clinical Effects. J Clin Oncol. 2021 05 01; 39(13):1415-1425.
    View in: PubMed
    Score: 0.007
  15. EBV/LMP-specific T cells maintain remissions of T- and B-cell EBV lymphomas after allogeneic bone marrow transplantation. Blood. 2018 11 29; 132(22):2351-2361.
    View in: PubMed
    Score: 0.006
  16. In?Vivo Fate and Activity of Second- versus Third-Generation CD19-Specific CAR-T Cells in B Cell Non-Hodgkin's Lymphomas. Mol Ther. 2018 12 05; 26(12):2727-2737.
    View in: PubMed
    Score: 0.006
  17. Treatment of Acute Myeloid Leukemia with T Cells Expressing Chimeric Antigen Receptors Directed to C-type Lectin-like Molecule 1. Mol Ther. 2017 09 06; 25(9):2202-2213.
    View in: PubMed
    Score: 0.005
  18. CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies. Blood. 2017 07 20; 130(3):285-296.
    View in: PubMed
    Score: 0.005
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.